Günay CAN, İsmet ŞAHİNLER, Meltem DAĞDELEN, Şefika Arzu ERGEN, Ceren BARLAS

The prognostic role of the pretreatment peripheralneutrophil-lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) in patients with cervical cancer

Aim: To investigate whether pretreatment peripheral neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) can beused as a prognostic indicator for predicting treatment response and survival outcomes in patients with cervical cancer. Materials and Methods: Records of 141 patients with histologic confirmation of squamous cell carcinoma of the uterine cervixwho were treated with radical radiotherapy or chemoradiotherapy in our clinic from 2010 to 2016 were retrospectively reviewedin this study. The relationship between pretreatment NLR/PLR with clinicopathological characteristics and therapeutic responseand survival was analyzed. The cut-off values of NLR and PLR that predicted treatment response were determined using a receiveroperating characteristic analysis. Results: In the clinicopathological analysis, while pretreatment elevated NLR was associated with the tumor size and grade, elevatedPLR was related to an advanced stage, tumor size and grade. Low NLR (

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Chemoradiotherapy for Cervical Cancer MetaAnalysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802-12.
3. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781-6.
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
6. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
7. Zhou X, Du Y, Huang Z, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 2014;9:e101119.
8. Sarraf KM, Belcher E, Raevsky E, et al. Neutrophil/ lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:425-8.
9. Walsh SR, Cook EJ, Goulder F, et al. Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181-4.
10. Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013;13:350.
11. Zhang X, Wang Y, Zhao L, et al. Prognostic value of platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and metaanalysis. Int J Biol Markers 1724600818766889.
12. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-51.
13. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013;108:901-7.
14. Lee YY, Choi CH, Kim HJ, et al. Pretreatment neutrophil: lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res 2012;32:1555-61.
15. Zhang Y, Wang L, Liu Y, et al. Preoperative neutrophillymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery. Int J Gynecol Cancer 2014 ;24:1319-25.
16. Nakamura K, Nishida T, Haruma T, et al. Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy. Mol Clin Oncol 2015;3:1001- 6.
17. Mizunuma M, Yokoyama Y, Futagami M, et al. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer. Int J Clin Oncol 2015;20:989-96.
18. Wu J, Chen M, Liang C, et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget 2017;8:13400-12.
19. Nuchpramool P, Hanprasertpong J. Preoperative Neutrophil-Lymphocyte Ratio and PlateletLymphocyte Ratio Are Not Clinically Useful in Predicting Prognosis in Early Stage Cervical Cancer. Surg Res Pract 2018;2018:9162921.
20. Prabawa IPY, Bhargah A, Liwang F, et.al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Plateletto-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev 2019;20:863-8.
21. Lee HJ, Kim JM, Chin YJ, et.al. Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy. Anticancer Res 2020;40:451-8.
22. Del Prete A, Allavena P, Santoro G, et al. Molecular pathways in cancer-related inflammation. Biochem Med 2011;21:264-75.
23. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436-44.
24. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
25. Chen L, Zhang F, Sheng XG, et al. Peripheral platelet/ lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte. Medicine 2016;95:e4381.